Diagn Cytopathol
The Road Ahead: Oral Dominance Is Not Inevitable Despite the growing commercial momentum surrounding oral GLP-1 therapies, the segment continues to face several important challenges that may affect long-term adoption and market expansion
Semaglutide: Your Body's "Fullness" Signal Let's start with semaglutide
Sunset from Kosciuszko Bridge, Hartaj Singh, March 2025 Upcoming Newsletter Events March 2025: Video podcast featuring the Biotech Blueprint
He was hospitalized for 13 days, undergoing several procedures to treat his condition
Why this matters: Tirzepatide alone already very powerful (15-22%) May already be optimizing GIP/GLP-1 pathways maximally Adding amylin might only add 2-5% more weight loss But could significantly increase side effects Risk-benefit ratio unknown Contrast with CagriSema: CagriSema: Extensively studied, Phase 3 trials, known safety Tirzepatide + cagrilintide: Zero studies, no safety data, speculative Learn about evidence-based approaches at SeekPeptides - explore best peptides for weight loss and best peptide stack for weight loss